1
|
Ahmed S, Alam W, Jeandet P, Aschner M, Alsharif KF, Saso L, Khan H. Therapeutic Potential of Marine Peptides in Prostate Cancer: Mechanistic Insights. Mar Drugs 2022; 20:md20080466. [PMID: 35892934 PMCID: PMC9330892 DOI: 10.3390/md20080466] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2022] [Revised: 07/15/2022] [Accepted: 07/18/2022] [Indexed: 02/07/2023] Open
Abstract
Prostate cancer (PCa) is the leading cause of cancer death in men, and its treatment is commonly associated with severe adverse effects. Thus, new treatment modalities are required. In this context, natural compounds have been widely explored for their anti-PCa properties. Aquatic organisms contain numerous potential medications. Anticancer peptides are less toxic to normal cells and provide an efficacious treatment approach via multiple mechanisms, including altered cell viability, apoptosis, cell migration/invasion, suppression of angiogenesis and microtubule balance disturbances. This review sheds light on marine peptides as efficacious and safe therapeutic agents for PCa.
Collapse
Affiliation(s)
- Salman Ahmed
- Department of Pharmacognosy, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi 75270, Pakistan;
| | - Waqas Alam
- Department of Pharmacy, Abdul Wali Khan University, Mardan 23200, Pakistan;
| | - Philippe Jeandet
- Research Unit “Induced Resistance and Plant Bioprotection”, Department of Biology and Biochemistry, Faculty of Sciences, University of Reims, EA 4707-USC INRAe 1488, SFR Condorcet FR CNRS 3417, P.O. Box 1039, CEDEX 02, 51687 Reims, France;
| | - Michael Aschner
- Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA;
| | - Khalaf F. Alsharif
- Department of Clinical Laboratory, College of Applied Medical Science, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia;
| | - Luciano Saso
- Department of Physiology and Pharmacology, “Vittorio Erspamer” Sapienza University, 00185 Rome, Italy;
| | - Haroon Khan
- Department of Pharmacy, Abdul Wali Khan University, Mardan 23200, Pakistan;
- Correspondence:
| |
Collapse
|
2
|
Timothy Grass Pollen Induces Spatial Reorganisation of F-Actin and Loss of Junctional Integrity in Respiratory Cells. Inflammation 2022; 45:1209-1223. [DOI: 10.1007/s10753-021-01614-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2021] [Revised: 12/08/2021] [Accepted: 12/13/2021] [Indexed: 12/12/2022]
|
3
|
McNeill SM, Giles NM, Preston D, Jones PP, Crowley JD, Giles GI. Quadruply Stranded Metallo-Supramolecular Helicate [Pd 2(hextrz) 4] 4+ Acts as a Molecular Mimic of Cytolytic Peptides. Chem Res Toxicol 2020; 33:1822-1834. [PMID: 32347099 DOI: 10.1021/acs.chemrestox.0c00061] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
[Pd2(hextrz)4]4+ is a quadruply stranded helicate, a novel bioinorganic complex designed to mimic the structure and function of proteins due to its high stability and supramolecular size. We have previously reported that [Pd2(hextrz)4]4+ exhibited cytotoxicity toward a range of cell lines, with IC50 values ranging from 3 to 10 μM. Here we demonstrate that [Pd2(hextrz)4]4+ kills cells by forming pores within the cell membrane, a mechanism of cell death analogous to the naturally occurring cytolytic peptides. [Pd2(hextrz)4]4+ induced cell death is characterized by an initial influx of Ca2+, followed by nuclear condensation and mitochondrial swelling. This is accompanied by progressive cell membrane damage that results in the formation of large blebs at the cell surface. This allows the efflux of molecules from the cell leading to loss of cell viability. These data suggest that it may be possible to design metallo-supramolecular complexes to mimic the cytotoxic action of pore forming proteins and peptides and so provide a new class of drug to treat cancer, autoimmune disorders, and microbial infection.
Collapse
Affiliation(s)
- Samantha M McNeill
- Department of Pharmacology and Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand
| | - Niroshini M Giles
- Department of Pharmacology and Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand
| | - Dan Preston
- Department of Chemistry, University of Otago, Dunedin, New Zealand
| | - Peter P Jones
- Department of Physiology and HeartOtago, University of Otago, Dunedin, New Zealand
| | - James D Crowley
- Department of Chemistry, University of Otago, Dunedin, New Zealand
| | - Gregory I Giles
- Department of Pharmacology and Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand
| |
Collapse
|
4
|
Benzodifurans for biomedical applications: BZ4, a selective anti-proliferative and anti-amyloid lead compound. Future Med Chem 2019; 11:285-302. [PMID: 30801198 DOI: 10.4155/fmc-2018-0473] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
AIM Our goal is to evaluate benzodifuran-based scaffolds for biomedical applications. METHODOLOGY We here explored the anticancer and anti-amyloid activities of a novel compound (BZ4) in comparison with other known benzodifuran analogs, previously studied in our group, and we have explored its ability to interact with different DNA model systems. RESULTS BZ4 shows antiproliferative activity on different cancer cells; does not affect noncancerous control cells and alters the aggregation properties of β-amyloid, as ascertained by circular dichroism, fluorescence spectroscopy and scanning electron microscopy analysis. An overall, qualitative picture on the mechanistic aspects related to the biological activities is discussed in light of the dynamic light scattering, UV, circular dichroism and fluorescence data, as well as of the metal ion-binding properties of BZ4.
Collapse
|
5
|
Peptides, Peptidomimetics, and Polypeptides from Marine Sources: A Wealth of Natural Sources for Pharmaceutical Applications. Mar Drugs 2017; 15:md15040124. [PMID: 28441741 PMCID: PMC5408270 DOI: 10.3390/md15040124] [Citation(s) in RCA: 68] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Revised: 04/11/2017] [Accepted: 04/18/2017] [Indexed: 01/07/2023] Open
Abstract
Nature provides a variety of peptides that are expressed in most living species. Evolutionary pressure and natural selection have created and optimized these peptides to bind to receptors with high affinity. Hence, natural resources provide an abundant chemical space to be explored in peptide-based drug discovery. Marine peptides can be extracted by simple solvent extraction techniques. The advancement of analytical techniques has made it possible to obtain pure peptides from natural resources. Extracted peptides have been evaluated as possible therapeutic agents for a wide range of diseases, including antibacterial, antifungal, antidiabetic and anticancer activity as well as cardiovascular and neurotoxin activity. Although marine resources provide thousands of possible peptides, only a few peptides derived from marine sources have reached the pharmaceutical market. This review focuses on some of the peptides derived from marine sources in the past ten years and gives a brief review of those that are currently in clinical trials or on the market.
Collapse
|
6
|
Musumeci D, Roviello GN, Rigione G, Capasso D, Di Gaetano S, Riccardi C, Roviello V, Montesarchio D. Benzodifuran Derivatives as Potential Antiproliferative Agents: Possible Correlation between Their Bioactivity and Aggregation Properties. Chempluschem 2016; 82:251-260. [PMID: 31961558 DOI: 10.1002/cplu.201600547] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2016] [Indexed: 01/24/2023]
Abstract
To further explore the properties and bioactivity of benzodifurans, three compounds in this class were synthesised and characterised using spectroscopic and spectrometric techniques, as well as SEM and thermogravimetric analysis. The synthesised compounds showed interesting antiproliferative activity on different human cancer cells (HeLa, Hep-G2, WM266), whereas no relevant cytotoxic effect was observed on healthy control cells. To study the possible mechanism of action of the benzodifurans, their ability to bind various model DNA systems, their aggregation properties, and their ability to bind biologically relevant metal ions was evaluated. The molecules were found to form monodisperse nanoaggregates stable at physiological temperature, which are likely related to the observed bioactivity.
Collapse
Affiliation(s)
- Domenica Musumeci
- Department of Chemical Sciences, University of Naples Federico II, Via Cintia 21, 80126, Naples, Italy.,Institute of Biostructures and Bioimaging, CNR, Via Mezzocannone 16, 80134, Naples, Italy
| | - Giovanni N Roviello
- Institute of Biostructures and Bioimaging, CNR, Via Mezzocannone 16, 80134, Naples, Italy
| | - Giuseppina Rigione
- Department of Chemical Sciences, University of Naples Federico II, Via Cintia 21, 80126, Naples, Italy
| | - Domenica Capasso
- Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, 80131, Naples, Italy
| | - Sonia Di Gaetano
- Institute of Biostructures and Bioimaging, CNR, Via Mezzocannone 16, 80134, Naples, Italy
| | - Claudia Riccardi
- Department of Chemical Sciences, University of Naples Federico II, Via Cintia 21, 80126, Naples, Italy
| | - Valentina Roviello
- Centro Regionale di Competenza (CRdC) Tecnologie, Via Nuova Agnano 11, 80125, Naples, Italy
| | - Daniela Montesarchio
- Department of Chemical Sciences, University of Naples Federico II, Via Cintia 21, 80126, Naples, Italy
| |
Collapse
|
7
|
Samipillai M, Bhatt N, Kruger HG, Govender T, Naicker T. Diverse supramolecular arrangement of substituted oxopyrrolidine analogues influenced by weak intermolecular interactions (CH⋯O/CH⋯π/H⋯H). J Mol Struct 2016. [DOI: 10.1016/j.molstruc.2016.05.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
8
|
Crystal structure of 2-ethyl-1- tert-butyl-2-((4-fluorophenyl)( tert-butoxycarbonylamino)methyl)-3-oxo-pyrrolidine-1,2-dicarboxylate, C 24H 33FN 2O 7. Z KRIST-NEW CRYST ST 2016. [DOI: 10.1515/ncrs-2015-0280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
C24H33FN2O7, triclinic, P1̅ (no. 2), a = 11.0118(7) Å, b = 11.5684(7) Å, c = 11.7276(7) Å, α = 112.294(1)°, β = 100.557(1)°, γ = 105.775(2)°, V = 1259.56(13) Å3, Z = 2, R
gt(F) = 0.0411, wR
ref(F
2) = 0.1050, T = 173 K.
Collapse
|
9
|
Phase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial). Cancer Chemother Pharmacol 2016; 77:819-27. [PMID: 26964995 DOI: 10.1007/s00280-016-2991-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Accepted: 02/10/2016] [Indexed: 12/11/2022]
Abstract
PURPOSE To determine the recommended dose and antitumor activity of single-agent elisidepsin as a 24-h intravenous (i.v.) infusion fortnightly [biweekly, d1 and 15 every 4 weeks (q4wk); Arm A, dose-intensity strategy] or as a 3-h i.v. infusion weekly (d1, 8, 15 and 22 q4wk; Arm B, dose-density strategy) in adult patients with unresectable, locally advanced or metastatic pretreated esophageal, gastroesophageal junction and gastric cancer. METHODS Patients were randomized to one of two elisidepsin dosing schedules. Phase Ib starting doses were 8.0 mg flat dose (FD) in Arm A and 3.0 mg FD in Arm B. Phase II subsequently explored antitumor activity of both dosing schedules at the respective recommended doses. RESULTS Forty-four patients received elisidepsin: 12 in stage Ib and 32 in stage II. The recommended doses were defined as 10 mg FD (Arm A) and 3.75 mg FD (Arm B). Both schedules were well tolerated. Most adverse events were mild or moderate, reversible and predictable with no meaningful differences between schedules. The pharmacokinetic profiles of both schedules were similar to those reported previously in patients with solid tumors treated with a comparable dose. An interim analysis found tumor control in one patient receiving elisidepsin fortnightly, and in none given elisidepsin weekly; patient accrual was therefore discontinued due to lack of efficacy. CONCLUSIONS Both schedules at the recommended doses presented an acceptable safety profile, but lack of response means that we do not recommend further evaluation of single-agent elisidepsin as chemotherapy for unresectable, locally advanced or metastatic gastroesophageal cancer.
Collapse
|
10
|
Bhatt N, Samipillai M, Das SK, Kruger HG, Govender T, Maguire GE. Crystal structure of 2-(ethoxycarbonyl)-2-(2-nitro-1-phenylethyl)-3-oxopyrrolidinium chloride, C 15H 19N 2O 5Cl. Z KRIST-NEW CRYST ST 2016. [DOI: 10.1515/ncrs-2014-9095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
C15H19N2O5Cl, triclinic, P1̅ (no. 2), a = 8.2232(9) Å, b = 8.5833(10) Å, c = 12.5916(13) Å, β = 100.713(5)°, V = 833.39 Å3, Z = 2, R
gt
(F) = 0.0331, wR
ref
(F
2
) = 0.0870, T = 173 K.
Collapse
Affiliation(s)
- Nilay Bhatt
- Catalysis and Peptide Research Unit, School of Health Sciences, University of, KwaZulu-Natal, Durban 4000, South Africa
| | - Marivale Samipillai
- Catalysis and Peptide Research Unit, School of Health Sciences, University of, KwaZulu-Natal, Durban 4000, South Africa
| | - Sukant Kishore Das
- Catalysis and Peptide Research Unit, School of Health Sciences, University of, KwaZulu-Natal, Durban 4000, South Africa
| | - Hendrik Gert Kruger
- Catalysis and Peptide Research Unit, School of Health Sciences, University of, KwaZulu-Natal, Durban 4000, South Africa
| | - Thavendran Govender
- Catalysis and Peptide Research Unit, School of Health Sciences, University of, KwaZulu-Natal, Durban 4000, South Africa
| | - Glenn E.M. Maguire
- Catalysis and Peptide Research Unit, School of Health Sciences, University of, KwaZulu-Natal, Durban 4000, South Africa
| |
Collapse
|
11
|
Goel S, Viteri S, Morán T, Coronado C, Dios JLI, Miguel-Lillo B, Fernández-García EM, Rosell R. Phase I, dose-escalating study of elisidepsin (Irvalec®), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors. Invest New Drugs 2015; 34:75-83. [DOI: 10.1007/s10637-015-0305-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2015] [Accepted: 11/08/2015] [Indexed: 11/29/2022]
|
12
|
Abstract
Cyclic depsipeptides are polypeptides in which one or more amino acid is replaced by a hydroxy acid, resulting in the formation of at least one ester bond in the core ring structure. Many natural cyclic depsipeptides possessing intriguing structural and biological properties, including antitumor, antifungal, antiviral, antibacterial, anthelmintic, and anti-inflammatory activities, have been identified from fungi, plants, and marine organisms. In particular, the potent effects of cyclic depsipeptides on tumor cells have led to a number of clinical trials evaluating their potential as chemotherapeutic agents. Although many of the trials have not achieved the desired results, romidepsin (FK228), a bicyclic depsipeptide that inhibits histone deacetylase, has been shown to have clinical efficacy in patients with refractory cutaneous T-cell lymphoma and has received Food and Drug Administration approval for use in treatment. In this review, we discuss antitumor cyclic depsipeptides that have undergone clinical trials and focus on their structural features, mechanisms, potential applications in chemotherapy, and pharmacokinetic and toxicity data. The results of this study indicate that cyclic depsipeptides could be a rich source of new cancer therapeutics.
Collapse
|
13
|
Molina-Guijarro JM, García C, Macías Á, García-Fernández LF, Moreno C, Reyes F, Martínez-Leal JF, Fernández R, Martínez V, Valenzuela C, Lillo MP, Galmarini CM. Elisidepsin Interacts Directly with Glycosylceramides in the Plasma Membrane of Tumor Cells to Induce Necrotic Cell Death. PLoS One 2015; 10:e0140782. [PMID: 26474061 PMCID: PMC4608773 DOI: 10.1371/journal.pone.0140782] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2015] [Accepted: 09/30/2015] [Indexed: 12/31/2022] Open
Abstract
Plasma membrane integrity is essential for cell life. Any major break on it immediately induces the death of the affected cell. Different molecules were described as disrupting this cell structure and thus showing antitumor activity. We have previously defined that elisidepsin (Irvalec®, PM02734) inserts and self-organizes in the plasma membrane of tumor cells, inducing a rapid loss of membrane integrity, cell permeabilization and necrotic death. Here we show that, in sensitive HCT-116 colorectal cells, all these effects are consequence of the interaction of elisidepsin with glycosylceramides in the cell membrane. Of note, an elisidepsin-resistant subline (HCT-116-Irv) presented reduced levels of glycosylceramides and no accumulation of elisidepsin in the plasma membrane. Consequently, drug treatment did not induce the characteristic necrotic cell death. Furthermore, GM95, a mutant derivative from B16 mouse melanoma cells lacking ceramide glucosyltransferase (UGCG) activity and thus the synthesis of glycosylceramides, was also resistant to elisidepsin. Over-expression of UGCG gene in these deficient cells restored glycosylceramides synthesis, rendering them sensitive to elisidepsin, at a similar level than parental B16 cells. These results indicate that glycosylceramides act as membrane targets of elisidepsin, facilitating its insertion in the plasma membrane and the subsequent membrane permeabilization that leads to drug-induced cell death. They also indicate that cell membrane lipids are a plausible target for antineoplastic therapy.
Collapse
Affiliation(s)
| | - Carolina García
- Departamento de Química Física Biológica, Instituto de Química-Física “Rocasolano” (CSIC), Madrid, Spain
| | - Álvaro Macías
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Madrid, Spain
| | | | - Cristina Moreno
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Madrid, Spain
| | - Fernando Reyes
- Fundación MEDINA, Parque Tecnológico de Ciencias de la Salud, Armilla, Granada, Spain
| | | | - Rogelio Fernández
- Departamento de Investigación y Desarrollo, PharmaMar S.A., Colmenar Viejo, Madrid, Spain
| | - Valentín Martínez
- Departamento de Investigación y Desarrollo, PharmaMar S.A., Colmenar Viejo, Madrid, Spain
| | - Carmen Valenzuela
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Madrid, Spain
| | - M. Pilar Lillo
- Departamento de Química Física Biológica, Instituto de Química-Física “Rocasolano” (CSIC), Madrid, Spain
| | - Carlos M. Galmarini
- Departamento de Investigación y Desarrollo, PharmaMar S.A., Colmenar Viejo, Madrid, Spain
| |
Collapse
|
14
|
Ratain MJ, Geary D, Undevia SD, Coronado C, Alfaro V, Iglesias JL, Schilsky RL, Miguel-Lillo B. First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. Invest New Drugs 2015; 33:901-10. [PMID: 25947566 DOI: 10.1007/s10637-015-0247-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2015] [Accepted: 04/29/2015] [Indexed: 11/26/2022]
Abstract
This first-in-human, phase I clinical trial was designed to determine the dose-limiting toxicities (DLTs) and the dose for phase II trials (P2D) of elisidepsin (PM02734) administered as a 30-min or as a 3-h intravenous infusion every 3 weeks (q3wk). Between March 2006 and April 2011, 53 patients with advanced malignant solid tumors were enrolled and treated with elisidepsin on the two different q3wk infusion schedules: 22 (30-min) and 31 (3-h), respectively. Doses evaluated ranged from 0.1 to 1.6 mg/m(2) (30-min q3wk) and from 2.0 to 11.0 mg flat dose (FD) (3-h q3wk). In the 30-min q3wk schedule, transient grade 3/4 increases in hepatic transaminases were the DLT, which appeared at the highest doses tested (from 1.1 to 1.6 mg/m(2)). No DLTs were observed on the 3-h schedule at doses up to 11.0 mg q3wk. Common adverse events were grade 1/2 pruritus, nausea, fatigue and hypersensitivity. Of note, myelotoxicity was not observed. Plasma maximum concentration and total drug exposure increased linearly with dose. Prolonged (≥3 months) disease stabilization was observed in pretreated patients with pleural mesothelioma (n = 1) in the 30-min q3wk arm, and with colorectal adenocarcinoma (n = 3), esophagus adenocarcinoma, endometrium adenocarcinoma, pleural mesothelioma, and head and neck carcinoma (n = 1 each) in the 3-h q3wk arm. In conclusion, elisidepsin doses of 1.1 mg/m(2) (equivalent to a FD of 2.0 mg) and 11.0 mg FD are the dose levels achieved for further phase II trials testing the 30-min q3wk and 3-h q3wk schedules, respectively.
Collapse
Affiliation(s)
- Mark J Ratain
- Department of Medicine, University of Chicago, MC2115, 5841 South Maryland Avenue, Chicago, IL, 60637, USA,
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Bastian A, Thorpe JE, Disch BC, Bailey-Downs LC, Gangjee A, Devambatla RKV, Henthorn J, Humphries KM, Vadvalkar SS, Ihnat MA. A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer. J Pharmacol Exp Ther 2015; 353:392-404. [PMID: 25720766 DOI: 10.1124/jpet.114.220335] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Therapy for treatment-resistant breast cancer provides limited options and the response rates are low. Therefore, the development of therapies with alternative chemotherapeutic strategies is necessary. AG311 (5-[(4-methylphenyl)thio]-9H-pyrimido[4,5-b]indole-2,4-diamine), a small molecule, is being investigated in preclinical and mechanistic studies for treatment of resistant breast cancer through necrosis, an alternative cell death mechanism. In vitro, AG311 induces rapid necrosis in numerous cancer cell lines as evidenced by loss of membrane integrity, ATP depletion, HMGB1 (high-mobility group protein B1) translocation, nuclear swelling, and stable membrane blebbing in breast cancer cells. Within minutes, exposure to AG311 also results in mitochondrial depolarization, superoxide production, and increased intracellular calcium levels. Additionally, upregulation of mitochondrial oxidative phosphorylation results in sensitization to AG311. This AG311-induced cell death can be partially prevented by treatment with the mitochondrial calcium uniporter inhibitor, Ru360 [(μ)[(HCO2)(NH3)4Ru]2OCl3], or an antioxidant, lipoic acid. Additionally, AG311 does not increase apoptotic markers such as cleavage of poly (ADP-ribose) polymerase (PARP) or caspase-3 and -7 activity. Importantly, in vivo studies in two orthotopic breast cancer mouse models (xenograft and allograft) demonstrate that AG311 retards tumor growth and reduces lung metastases better than clinically used agents and has no gross or histopathological toxicity. Together, these data suggest that AG311 is a first-in-class antitumor and antimetastatic agent inducing necrosis in breast cancer tumors, likely through the mitochondria.
Collapse
Affiliation(s)
- Anja Bastian
- Department of Pharmaceutical Sciences (A.B., J.E.T., B.C.D., M.A.I.), Department of Physiology (A.B.), Flow Cytometry and Imaging Laboratory (J.H.), University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; DormaTarg, Inc., Oklahoma City, Oklahoma (B.C.D., L.C.B.D., M.A.I.); Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, Pennsylvania (A.G., R.K.V.D.); and Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma (K.M.H., S.S.V.)
| | - Jessica E Thorpe
- Department of Pharmaceutical Sciences (A.B., J.E.T., B.C.D., M.A.I.), Department of Physiology (A.B.), Flow Cytometry and Imaging Laboratory (J.H.), University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; DormaTarg, Inc., Oklahoma City, Oklahoma (B.C.D., L.C.B.D., M.A.I.); Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, Pennsylvania (A.G., R.K.V.D.); and Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma (K.M.H., S.S.V.)
| | - Bryan C Disch
- Department of Pharmaceutical Sciences (A.B., J.E.T., B.C.D., M.A.I.), Department of Physiology (A.B.), Flow Cytometry and Imaging Laboratory (J.H.), University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; DormaTarg, Inc., Oklahoma City, Oklahoma (B.C.D., L.C.B.D., M.A.I.); Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, Pennsylvania (A.G., R.K.V.D.); and Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma (K.M.H., S.S.V.)
| | - Lora C Bailey-Downs
- Department of Pharmaceutical Sciences (A.B., J.E.T., B.C.D., M.A.I.), Department of Physiology (A.B.), Flow Cytometry and Imaging Laboratory (J.H.), University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; DormaTarg, Inc., Oklahoma City, Oklahoma (B.C.D., L.C.B.D., M.A.I.); Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, Pennsylvania (A.G., R.K.V.D.); and Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma (K.M.H., S.S.V.)
| | - Aleem Gangjee
- Department of Pharmaceutical Sciences (A.B., J.E.T., B.C.D., M.A.I.), Department of Physiology (A.B.), Flow Cytometry and Imaging Laboratory (J.H.), University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; DormaTarg, Inc., Oklahoma City, Oklahoma (B.C.D., L.C.B.D., M.A.I.); Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, Pennsylvania (A.G., R.K.V.D.); and Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma (K.M.H., S.S.V.)
| | - Ravi K V Devambatla
- Department of Pharmaceutical Sciences (A.B., J.E.T., B.C.D., M.A.I.), Department of Physiology (A.B.), Flow Cytometry and Imaging Laboratory (J.H.), University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; DormaTarg, Inc., Oklahoma City, Oklahoma (B.C.D., L.C.B.D., M.A.I.); Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, Pennsylvania (A.G., R.K.V.D.); and Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma (K.M.H., S.S.V.)
| | - Jim Henthorn
- Department of Pharmaceutical Sciences (A.B., J.E.T., B.C.D., M.A.I.), Department of Physiology (A.B.), Flow Cytometry and Imaging Laboratory (J.H.), University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; DormaTarg, Inc., Oklahoma City, Oklahoma (B.C.D., L.C.B.D., M.A.I.); Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, Pennsylvania (A.G., R.K.V.D.); and Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma (K.M.H., S.S.V.)
| | - Kenneth M Humphries
- Department of Pharmaceutical Sciences (A.B., J.E.T., B.C.D., M.A.I.), Department of Physiology (A.B.), Flow Cytometry and Imaging Laboratory (J.H.), University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; DormaTarg, Inc., Oklahoma City, Oklahoma (B.C.D., L.C.B.D., M.A.I.); Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, Pennsylvania (A.G., R.K.V.D.); and Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma (K.M.H., S.S.V.)
| | - Shraddha S Vadvalkar
- Department of Pharmaceutical Sciences (A.B., J.E.T., B.C.D., M.A.I.), Department of Physiology (A.B.), Flow Cytometry and Imaging Laboratory (J.H.), University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; DormaTarg, Inc., Oklahoma City, Oklahoma (B.C.D., L.C.B.D., M.A.I.); Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, Pennsylvania (A.G., R.K.V.D.); and Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma (K.M.H., S.S.V.)
| | - Michael A Ihnat
- Department of Pharmaceutical Sciences (A.B., J.E.T., B.C.D., M.A.I.), Department of Physiology (A.B.), Flow Cytometry and Imaging Laboratory (J.H.), University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; DormaTarg, Inc., Oklahoma City, Oklahoma (B.C.D., L.C.B.D., M.A.I.); Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, Pennsylvania (A.G., R.K.V.D.); and Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma (K.M.H., S.S.V.)
| |
Collapse
|
16
|
The first total synthesis of the cyclodepsipeptide pipecolidepsin A. Nat Commun 2014; 4:2352. [PMID: 23989475 DOI: 10.1038/ncomms3352] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2013] [Accepted: 07/24/2013] [Indexed: 01/04/2023] Open
Abstract
Pipecolidepsin A is a head-to-side-chain cyclodepsipeptide isolated from the marine sponge Homophymia lamellosa. This compound shows relevant cytotoxic activity in three human tumour cell lines and has unique structural features, with an abundance of non-proteinogenic residues, including several intriguing amino acids. Although the moieties present in the structure show high synthetic difficulty, the cornerstone is constituted by the unprecedented and highly hindered γ-branched β-hydroxy-α-amino acid D-allo-(2R,3R,4R)-2-amino-3-hydroxy-4,5-dimethylhexanoic acid (AHDMHA) residue, placed at the branching ester position and surrounded by the four demanding residues L-(2S,3S,4R)-3,4-dimethylglutamine, (2R,3R,4S)-4,7-diamino-2,3-dihydroxy-7-oxoheptanoic acid, D-allo-Thr and L-pipecolic acid. Here we describe the first total synthesis of a D-allo-AHDMHA-containing peptide, pipecolidepsin A, thus allowing chemical structure validation of the natural product and providing a robust synthetic strategy to access other members of the relevant head-to-side-chain family in a straightforward manner.
Collapse
|
17
|
Co-cultivation--a powerful emerging tool for enhancing the chemical diversity of microorganisms. Mar Drugs 2014; 12:1043-65. [PMID: 24549204 PMCID: PMC3944530 DOI: 10.3390/md12021043] [Citation(s) in RCA: 207] [Impact Index Per Article: 20.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2014] [Revised: 01/23/2014] [Accepted: 02/06/2014] [Indexed: 02/03/2023] Open
Abstract
Marine-derived bacteria and fungi are promising sources of novel bioactive compounds that are important for drug discovery programs. However, as encountered in terrestrial microorganisms there is a high rate of redundancy that results in the frequent re-discovery of known compounds. Apparently only a part of the biosynthetic genes that are harbored by fungi and bacteria are transcribed under routine laboratory conditions which involve cultivation of axenic microbial strains. Many biosynthetic genes remain silent and are not expressed in vitro thereby seriously limiting the chemical diversity of microbial compounds that can be obtained through fermentation. In contrast to this, co-cultivation (also called mixed fermentation) of two or more different microorganisms tries to mimic the ecological situation where microorganisms always co-exist within complex microbial communities. The competition or antagonism experienced during co-cultivation is shown to lead to a significantly enhanced production of constitutively present compounds and/or to an accumulation of cryptic compounds that are not detected in axenic cultures of the producing strain. This review highlights the power of co-cultivation for increasing the chemical diversity of bacteria and fungi drawing on published studies from the marine and from the terrestrial habitat alike.
Collapse
|
18
|
Goldwasser F, Faivre S, Alexandre J, Coronado C, Fernández-García EM, Kahatt CM, Paramio PG, Dios JLI, Miguel-Lillo B, Raymond E. Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies. Invest New Drugs 2014; 32:500-9. [DOI: 10.1007/s10637-013-0060-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2013] [Accepted: 12/26/2013] [Indexed: 12/16/2022]
|
19
|
Király A, Váradi T, Hajdu T, Rühl R, Galmarini CM, Szöllősi J, Nagy P. Hypoxia reduces the efficiency of elisidepsin by inhibiting hydroxylation and altering the structure of lipid rafts. Mar Drugs 2013; 11:4858-75. [PMID: 24317474 PMCID: PMC3877891 DOI: 10.3390/md11124858] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2013] [Revised: 10/26/2013] [Accepted: 11/05/2013] [Indexed: 12/18/2022] Open
Abstract
The mechanism of action of elisidepsin (PM02734, Irvalec®) is assumed to involve membrane permeabilization via attacking lipid rafts and hydroxylated lipids. Here we investigate the role of hypoxia in the mechanism of action of elisidepsin. Culturing under hypoxic conditions increased the half-maximal inhibitory concentration and decreased the drug’s binding to almost all cell lines which was reversed by incubation of cells with 2-hydroxy palmitic acid. The expression of fatty acid 2-hydroxylase was strongly correlated with the efficiency of the drug and inversely correlated with the effect of hypoxia. Number and brightness analysis and fluorescence anisotropy experiments showed that hypoxia decreased the clustering of lipid rafts and altered the structure of the plasma membrane. Although the binding of elisidepsin to the membrane is non-cooperative, its membrane permeabilizing effect is characterized by a Hill coefficient of ~3.3. The latter finding is in agreement with elisidepsin-induced clusters of lipid raft-anchored GFP visualized by confocal microscopy. We propose that the concentration of elisidepsin needs to reach a critical level in the membrane above which elisidepsin induces the disruption of the cell membrane. Testing for tumor hypoxia or the density of hydroxylated lipids could be an interesting strategy to increase the efficiency of elisidepsin.
Collapse
Affiliation(s)
- Anna Király
- Department of Biophysics and Cell Biology, University of Debrecen, Nagyerdei krt. 98, Debrecen 4032, Hungary; E-Mails: (A.K.); (T.V.); (T.H.); (J.S.)
| | - Tímea Váradi
- Department of Biophysics and Cell Biology, University of Debrecen, Nagyerdei krt. 98, Debrecen 4032, Hungary; E-Mails: (A.K.); (T.V.); (T.H.); (J.S.)
| | - Tímea Hajdu
- Department of Biophysics and Cell Biology, University of Debrecen, Nagyerdei krt. 98, Debrecen 4032, Hungary; E-Mails: (A.K.); (T.V.); (T.H.); (J.S.)
| | - Ralph Rühl
- Department of Biochemistry and Molecular Biology, University of Debrecen, Nagyerdei krt. 98, Debrecen 4032, Hungary; E-Mail:
| | - Carlos M. Galmarini
- Cell Biology Department, PharmaMar, Avda de los Reyes 1, Pol. Ind. La Mina, Colmenar Viejo, Madrid 28770, Spain; E-Mail:
| | - János Szöllősi
- Department of Biophysics and Cell Biology, University of Debrecen, Nagyerdei krt. 98, Debrecen 4032, Hungary; E-Mails: (A.K.); (T.V.); (T.H.); (J.S.)
- MTA-DE Cell Biology and Signaling Research Group, University of Debrecen, Nagyerdei krt. 98, Debrecen 4032, Hungary
| | - Peter Nagy
- Department of Biophysics and Cell Biology, University of Debrecen, Nagyerdei krt. 98, Debrecen 4032, Hungary; E-Mails: (A.K.); (T.V.); (T.H.); (J.S.)
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +36-52-412-623; Fax: +36-52-532-201
| |
Collapse
|
20
|
Camunas-Soler J, Frutos S, Bizarro CV, de Lorenzo S, Fuentes-Perez ME, Ramsch R, Vilchez S, Solans C, Moreno-Herrero F, Albericio F, Eritja R, Giralt E, Dev SB, Ritort F. Electrostatic binding and hydrophobic collapse of peptide-nucleic acid aggregates quantified using force spectroscopy. ACS NANO 2013; 7:5102-5113. [PMID: 23706043 DOI: 10.1021/nn4007237] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Knowledge of the mechanisms of interaction between self-aggregating peptides and nucleic acids or other polyanions is key to the understanding of many aggregation processes underlying several human diseases (e.g., Alzheimer's and Parkinson's diseases). Determining the affinity and kinetic steps of such interactions is challenging due to the competition between hydrophobic self-aggregating forces and electrostatic binding forces. Kahalalide F (KF) is an anticancer hydrophobic peptide that contains a single positive charge that confers strong aggregative properties with polyanions. This makes KF an ideal model to elucidate the mechanisms by which self-aggregation competes with binding to a strongly charged polyelectrolyte such as DNA. We use optical tweezers to apply mechanical forces to single DNA molecules and show that KF and DNA interact in a two-step kinetic process promoted by the electrostatic binding of DNA to the aggregate surface followed by the stabilization of the complex due to hydrophobic interactions. From the measured pulling curves we determine the spectrum of binding affinities, kinetic barriers, and lengths of DNA segments sequestered within the KF-DNA complex. We find there is a capture distance beyond which the complex collapses into compact aggregates stabilized by strong hydrophobic forces and discuss how the bending rigidity of the nucleic acid affects this process. We hypothesize that within an in vivo context, the enhanced electrostatic interaction of KF due to its aggregation might mediate the binding to other polyanions. The proposed methodology should be useful to quantitatively characterize other compounds or proteins in which the formation of aggregates is relevant.
Collapse
Affiliation(s)
- Joan Camunas-Soler
- Small Biosystems Lab, Departament de Física Fonamental, Universitat de Barcelona, Avinguda Diagonal 647, 08028 Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Serova M, de Gramont A, Bieche I, Riveiro ME, Galmarini CM, Aracil M, Jimeno J, Faivre S, Raymond E. Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound. Mar Drugs 2013; 11:944-59. [PMID: 23519149 PMCID: PMC3705381 DOI: 10.3390/md11030944] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2012] [Revised: 01/21/2013] [Accepted: 02/22/2013] [Indexed: 01/20/2023] Open
Abstract
Elisidepsin (PM02734, Irvalec®) is a synthetic marine-derived cyclic peptide of the Kahalalide F family currently in phase II clinical development. Elisidepsin was shown to induce rapid oncosis in ErbB3-expressing cells. Other predictive factors of elisidepsin sensitivity remained unknown. A panel of 23 cancer cell lines of different origin was assessed for elisidepsin cytotoxicity and correlated with mutational state, mRNA and protein expression of selected genes. Elisidepsin showed potent and broad cytotoxic effects in our cancer cell line panel, being active at concentrations ranging from 0.4 to 2 μM that may be relevant for clinical settings. We have shown that elisidepsin is more active in cells harboring epithelial phenotype with high E-cadherin and low vimentin expression. In addition, high ErbB3 and Muc1 expression was correlated with sensitivity to elisidepsin, whereas the presence of KRAS activating mutations was associated with resistance. In DU-PM cells with acquired resistance to elisidepsin, ErbB3 expression was decreased, while Bcl2 was increased. DU-PM cells displayed higher sensitivity to ErbB1-inhibitors suggesting possible cross-talk of ErbB1 and ErbB3 signaling pathways. Combinations of elisidepsin with lapatinib and several chemotherapies including 5-FU and oxaliplatin resulted in synergistic effects that offer the potential of clinical use of elisidepsin in combination settings.
Collapse
Affiliation(s)
- Maria Serova
- AAREC Filia Research, 1, Paul Verlaine, Boulogne Billancourt 92100, France; E-Mails: (M.S.); (A.G.)
- INSERM U728 and Departments of Medical Oncology, Beaujon University Hospital (AP-HP-Paris 7 Diderot), 100, bd General Leclerc, Clichy 92110, France; E-Mails: (M.E.R.); (S.F.)
| | - Armand de Gramont
- AAREC Filia Research, 1, Paul Verlaine, Boulogne Billancourt 92100, France; E-Mails: (M.S.); (A.G.)
- INSERM U728 and Departments of Medical Oncology, Beaujon University Hospital (AP-HP-Paris 7 Diderot), 100, bd General Leclerc, Clichy 92110, France; E-Mails: (M.E.R.); (S.F.)
| | - Ivan Bieche
- Laboratory of Molecular Genetics, Beaujon University Hospital, Paris 7 Diderot, 100, bd General Leclerc, Clichy 92110, France; E-Mail:
| | - Maria Eugenia Riveiro
- INSERM U728 and Departments of Medical Oncology, Beaujon University Hospital (AP-HP-Paris 7 Diderot), 100, bd General Leclerc, Clichy 92110, France; E-Mails: (M.E.R.); (S.F.)
| | - Carlos Maria Galmarini
- Cell Biology Department, PharmaMar, Avda de los Reyes 1, Pol. Ind. La Mina, Colmenar Viejo (Madrid) 28770, Spain; E-Mails: (C.M.G.); (M.A.); (J.J.)
| | - Miguel Aracil
- Cell Biology Department, PharmaMar, Avda de los Reyes 1, Pol. Ind. La Mina, Colmenar Viejo (Madrid) 28770, Spain; E-Mails: (C.M.G.); (M.A.); (J.J.)
| | - José Jimeno
- Cell Biology Department, PharmaMar, Avda de los Reyes 1, Pol. Ind. La Mina, Colmenar Viejo (Madrid) 28770, Spain; E-Mails: (C.M.G.); (M.A.); (J.J.)
| | - Sandrine Faivre
- INSERM U728 and Departments of Medical Oncology, Beaujon University Hospital (AP-HP-Paris 7 Diderot), 100, bd General Leclerc, Clichy 92110, France; E-Mails: (M.E.R.); (S.F.)
| | - Eric Raymond
- INSERM U728 and Departments of Medical Oncology, Beaujon University Hospital (AP-HP-Paris 7 Diderot), 100, bd General Leclerc, Clichy 92110, France; E-Mails: (M.E.R.); (S.F.)
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +33-1-4087-5614; Fax: +33-1-4087-5487
| |
Collapse
|
22
|
Zheng L, Lin X, Wu N, Liu M, Zheng Y, Sheng J, Ji X, Sun M. Targeting cellular apoptotic pathway with peptides from marine organisms. Biochim Biophys Acta Rev Cancer 2013; 1836:42-8. [PMID: 23470652 DOI: 10.1016/j.bbcan.2013.02.006] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2013] [Revised: 02/17/2013] [Accepted: 02/19/2013] [Indexed: 01/15/2023]
Abstract
Apoptosis is a critical defense mechanism against the formation and progression of cancer and exhibits distinct morphological and biochemical traits. Targeting apoptotic pathways becomes an intriguing strategy for the development of chemotherapeutic agents. Peptides from marine organisms have become important sources in the discovery of antitumor drugs, especially when modern technology makes it more and more feasible to collect organisms from seas. This primer summarizes several marine peptides, based on their effects on apoptotic signaling pathways, although most of these peptides have not yet been studied in depth for their mechanisms of action. Novel peptides that induce an apoptosis signal pathway are presented in association with their pharmacological properties.
Collapse
Affiliation(s)
- Lanhong Zheng
- Yellow Sea Fisheries Research Institute, Chinese Academy of Fishery Sciences, Qingdao, China
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Teixidó C, Marés R, Aracil M, Ramón y Cajal S, Hernández-Losa J. Epithelial-mesenchymal transition markers and HER3 expression are predictors of elisidepsin treatment response in breast and pancreatic cancer cell lines. PLoS One 2013; 8:e53645. [PMID: 23320098 PMCID: PMC3539985 DOI: 10.1371/journal.pone.0053645] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2012] [Accepted: 12/03/2012] [Indexed: 12/23/2022] Open
Abstract
Elisidepsin (elisidepsin trifluoroacetate, Irvalec®, PM02734) is a new synthetic depsipeptide, a result of the PharmaMar Development Program that seeks synthetic products of marine origin-derived compounds. Elisidepsin is a drug with antiproliferative activity in a wide range of tumors. In the present work we studied and characterized the mechanisms associated with sensitivity and resistance to elisidepsin treatment in a broad panel of tumor cell lines from breast and pancreas carcinomas, focusing on different factors involved in epithelial-mesenchymal transition (EMT) and the use of HER family receptors in predicting the in vitro drug response. Interestingly, we observed that the basal protein expression levels of EMT markers show a significant correlation with cell viability in response to elisidepsin treatment in a panel of 12 different breast and pancreatic cancer cell lines. In addition, we generated three elisidepsin treatment-resistant cell lines (MCF-7, HPAC and AsPC-1) and analyzed the pattern of expression of different EMT markers in these cells, confirming that acquired resistance to elisidepsin is associated with a switch to the EMT state. Furthermore, a direct correlation between basal HER3 expression and sensitivity to elisidepsin was observed; moreover, modulation of HER3 expression levels in different cancer cell lines alter their sensitivities to the drug, making them more resistant when HER3 expression is downregulated by a HER3-specific short hairpin RNA and more sensitive when the receptor is overexpressed. These results show that HER3 expression is an important marker of sensitivity to elisidepsin treatment.
Collapse
Affiliation(s)
- Cristina Teixidó
- Molecular Pathology Group, Vall d’Hebron Research Institute, Universidad Autonoma of Barcelona, Barcelona, Spain
| | - Rosó Marés
- Molecular Pathology Group, Vall d’Hebron Research Institute, Universidad Autonoma of Barcelona, Barcelona, Spain
| | | | - Santiago Ramón y Cajal
- Pathology Department, Vall d’Hebron University Hospital, Universidad Autonoma of Barcelona, Barcelona, Spain
| | - Javier Hernández-Losa
- Pathology Department, Vall d’Hebron University Hospital, Universidad Autonoma of Barcelona, Barcelona, Spain
| |
Collapse
|
24
|
Salazar R, Jones RJ, Oaknin A, Crawford D, Cuadra C, Hopkins C, Gil M, Coronado C, Soto-Matos A, Cullell-Young M, Iglesias Dios JL, Evans TRJ. A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors. Cancer Chemother Pharmacol 2012; 70:673-81. [DOI: 10.1007/s00280-012-1951-6] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2012] [Accepted: 08/02/2012] [Indexed: 02/05/2023]
|
25
|
Váradi T, Roszik J, Lisboa D, Vereb G, Molina-Guijarro JM, Galmarini CM, Szöllősi J, Nagy P. ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment. Eur J Pharmacol 2011; 667:91-9. [DOI: 10.1016/j.ejphar.2011.05.064] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2010] [Revised: 05/07/2011] [Accepted: 05/22/2011] [Indexed: 01/30/2023]
|